Latest filings (excl ownership)
8-K
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
8 Oct 24
10-Q
2024 Q2
Quarterly report
13 Aug 24
8-K
Pulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate Update
13 Aug 24
8-K
Departure of Directors or Certain Officers
19 Jul 24
EFFECT
Notice of effectiveness
31 May 24
8-K
Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation
29 May 24
S-3
Shelf registration
17 May 24
8-K
Regulation FD Disclosure
15 May 24
10-Q
2024 Q1
Quarterly report
10 May 24
8-K
Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update
10 May 24
424B3
Prospectus supplement
28 Mar 24
10-K
2023 FY
Annual report
28 Mar 24
8-K
Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update
28 Mar 24
8-K
Departure of Directors or Certain Officers
13 Mar 24
8-K
Regulation FD Disclosure
4 Mar 24
8-K
Entry into a Material Definitive Agreement
8 Jan 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update
9 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update
10 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
13 Jul 23
8-K
Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine
11 Jul 23
ARS
2022 FY
Annual report to shareholders
2 Jun 23
DEF 14A
Definitive proxy
2 Jun 23
10-Q
2023 Q1
Quarterly report
12 May 23
8-K
Pulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate Update
12 May 23
10-K
2022 FY
Annual report
30 Mar 23
8-K
Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update
30 Mar 23
8-K
Regulation FD Disclosure
6 Feb 23
8-K
Regulation FD Disclosure
3 Feb 23
8-K
Regulation FD Disclosure
25 Jan 23
8-K
Regulation FD Disclosure
11 Jan 23
8-K
Pulmatrix Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine (DHE), for Acute Migraine
4 Jan 23
8-K
Pulmatrix Announces Third Quarter 2022 Financial Results and Provides Corporate Update
14 Nov 22
10-Q
2022 Q3
Quarterly report
10 Nov 22
8-K
Pulmatrix Announces Patient Dosing Completed for its Novel Inhaled Therapy PUR3100 for Acute Migraine
26 Sep 22
10-Q
2022 Q2
Quarterly report
10 Aug 22
8-K
Pulmatrix Announces Second Quarter 2022 Financial Results and Provides Corporate Update
10 Aug 22
424B3
Prospectus supplement
9 Aug 22
8-K
Pulmatrix Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine
12 Jul 22
Latest ownership filings
SC 13G/A
SABBY MANAGEMENT, LLC
2 Jan 24
SC 13G/A
INTRACOASTAL CAPITAL, LLC
8 Feb 23
4
Michelle Siegert
30 Jan 23
4
Margaret Wasilewski
30 Jan 23
4
Teofilo David Raad
30 Jan 23
4
Todd Bazemore
30 Jan 23
4
Michael J Higgins
30 Jan 23
4
Christopher Cabell
30 Jan 23
4
Anand Varadan
30 Jan 23
4
Richard P. Batycky
30 Jan 23
SC 13G/A
SABBY MANAGEMENT, LLC
10 Jan 23
3
Peter Ludlum
19 Apr 22
4
Margaret Wasilewski
3 Mar 22
3
Margaret Wasilewski
3 Mar 22
SC 13G/A
CVI Investments, Inc.
14 Feb 22
SC 13G/A
INTRACOASTAL CAPITAL, LLC
11 Feb 22
SC 13G/A
RENAISSANCE TECHNOLOGIES LLC
10 Feb 22
4
Michael J Higgins
31 Jan 22
4
Richard P. Batycky
31 Jan 22
4
Christopher Cabell
31 Jan 22
4
Todd Bazemore
28 Jan 22
4
Anand Varadan
28 Jan 22
4
Michelle Siegert
28 Jan 22
4
Teofilo David Raad
28 Jan 22
SC 13G/A
SABBY MANAGEMENT, LLC
5 Jan 22
4
Anand Varadan
28 Jul 21
3
Anand Varadan
28 Jul 21
SC 13D
FiveT Investment Management Ltd
25 Feb 21
SC 13G
CVI Investments, Inc.
24 Feb 21
SC 13G/A
CVI Investments, Inc.
16 Feb 21
SC 13G
RENAISSANCE TECHNOLOGIES LLC
10 Feb 21
4
Amit Munshi
1 Feb 21
4
Mark T Iwicki
1 Feb 21
4
Christopher Cabell
1 Feb 21
4
Michelle Siegert
1 Feb 21
4
Todd Bazemore
1 Feb 21
4
Michael J Higgins
1 Feb 21
4
Teofilo David Raad
1 Feb 21
4
Richard P. Batycky
1 Feb 21
SC 13G/A
INTRACOASTAL CAPITAL, LLC
29 Jan 21